Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, Kathy S. Albain et al.|Cancer Research|2021Cited by 88
Temporal evolution of breast cancer brain metastases treatments and outcomesMichele Bottosso, Valentina Guarneri, Gaia Griguolo et al.|npj Breast Cancer|2025Cited by 6